- Companies
- RxSight
RxSight Valuation Multiples
RxSight is valued at $188M as of October 2026. In the last 12 months, RxSight revenue was $144M and RxSight EBITDA was ($47M).
RxSight Overview
About RxSight
RxSight Inc is a commercial-stage medical technology company dedicated towards improving the vision of patients following cataract surgery. It offers intraocular lens technology that enables doctors to customize and optimize visual acuity for patients after cataract surgery. The company operates and manages its business in one reportable segment, the research and development, manufacture and sale of light adjustable lenses and related capital equipment.
Founded
1997
HQ
Employees
498
Website
Financials (LTM)
Market Cap
$188M
Valuation Multiples
Start free trialRxSight Financials
RxSight reported last 12-month revenue of $144M and negative EBITDA of ($47M).
In the same LTM period, RxSight generated $112M in gross profit, ($47M) in EBITDA losses, and had net loss of ($39M).
Revenue (LTM)
RxSight P&L
In the most recent fiscal year, RxSight reported revenue of $134M and EBITDA of ($45M).
RxSight is unprofitable as of last fiscal year, with gross margin of 77%, EBITDA margin of (33%), and net margin of (29%).
Financial data powered by Morningstar, Inc.
RxSight Stock Performance
RxSight has current market cap of $188M.
Market Cap Evolution
RxSight's stock price is $4.51.
RxSight share price decreased by 8.0% in the last 30 days, and by 48.4% in the last year.
RxSight has an EPS (earnings per share) of $-0.94.
| Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|
| $188M | 0.0% | -8.0% | -24.6% | -48.4% | $-0.94 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialRxSight Valuation Multiples
RxSight Financial Valuation Multiples
As of October 18, 2026, RxSight has market cap of $188M.
RxSight has a P/E ratio of (4.8x).
Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified RxSight Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.


RxSight Margins & Growth Rates
RxSight grew revenue by 9% and EBITDA by 6% in the last fiscal year.
In the most recent fiscal year, RxSight reported gross margin of 77%, EBITDA margin of (33%), and net margin of (29%).
RxSight Margins
RxSight Growth Rates
Data powered by FactSet, Inc. and Morningstar, Inc.
RxSight Operational KPIs
RxSight's revenue per employee in the last FY averaged $0.3M, while opex per employee averaged $0.3M for the same period.
RxSight's Rule of 40 is (23%) (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
RxSight's Rule of X is (9%) (created by Bessemer, Rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Data powered by FactSet, Inc. and Morningstar, Inc.
RxSight Competitors
RxSight competitors include Pro-Dex, AOTI, Onward Medical, Edap TMS, BICO Group, JETEMA Co., Inogen, Huons Co, Ilex Medical and Profound Medical.
Most RxSight public comparables operate across Medical Devices, DeepTech and HealthTech.
| Last FY | EV/Revenue | EV/EBITDA | ||||||
|---|---|---|---|---|---|---|---|---|
| Revenue | EBITDA | Last FY | LTM | 2027E | Last FY | LTM | 2027E | |
| $78M | $20M | 2.6x | 2.5x | 9.9x | 13.1x | |||
| $67M | $8M | 2.9x | 2.7x | 25.3x | 27.5x | |||
| $4M | ($43M) | 25.2x | 8.7x | (2.5x) | (1.9x) | |||
| $71M | ($25M) | 3.0x | 3.8x | (8.6x) | (6.9x) | |||
| $151M | ($132M) | 1.2x | 1.1x | (1.4x) | 20.6x | |||
| $57M | $8M | 4.1x | - | 28.5x | - | |||
| $349M | ($7M) | 0.2x | 0.2x | (10.7x) | 20.6x | |||
| $463M | $60M | 0.6x | - | 4.3x | - | |||
This data is available for Pro users. Sign up to see all RxSight competitors and their valuation data. Start Free Trial | ||||||||
RxSight VC Funding History
Before going public, RxSight raised $95M in total equity funding, across 4 rounds.
RxSight Funding Rounds
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout RxSight
| When was RxSight founded? | RxSight was founded in 1997. |
| Where is RxSight headquartered? | RxSight is headquartered in United States. |
| How many employees does RxSight have? | As of today, RxSight has over 498 employees. |
| Who is the CEO of RxSight? | RxSight's CEO is Ron Kurtz. |
| Is RxSight publicly listed? | Yes, RxSight is a public company listed on Nasdaq. |
| What is the stock symbol of RxSight? | RxSight trades under RXST ticker. |
| When did RxSight go public? | RxSight went public in 2021. |
| Who are competitors of RxSight? | RxSight main competitors include Pro-Dex, AOTI, Onward Medical, Edap TMS, BICO Group, JETEMA Co., Inogen, Huons Co, Ilex Medical, Profound Medical. |
| What is the current market cap of RxSight? | RxSight's current market cap is $188M. |
| What is the current revenue of RxSight? | RxSight's last 12 months revenue is $144M. |
| What is the current revenue growth of RxSight? | RxSight revenue growth (NTM/LTM) is 3%. |
| Is RxSight profitable? | No, RxSight is not profitable. |
| What is the current EBITDA of RxSight? | RxSight has negative EBITDA and is not profitable. |
| What is RxSight's EBITDA margin? | RxSight's last 12 months EBITDA margin is (33%). |
| What is the current FCF of RxSight? | RxSight's last 12 months FCF is ($26M). |
| What is RxSight's FCF margin? | RxSight's last 12 months FCF margin is (18%). |
| How many companies RxSight has acquired to date? | RxSight hasn't acquired any companies yet (or none have been disclosed publicly). |
| In how many companies RxSight has invested to date? | RxSight hasn't invested in any companies yet (or none have been disclosed publicly). |
See public comps similar to RxSight
Lists including RxSight
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.




